JP2017535528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535528A5 JP2017535528A5 JP2017517730A JP2017517730A JP2017535528A5 JP 2017535528 A5 JP2017535528 A5 JP 2017535528A5 JP 2017517730 A JP2017517730 A JP 2017517730A JP 2017517730 A JP2017517730 A JP 2017517730A JP 2017535528 A5 JP2017535528 A5 JP 2017535528A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- cancer
- inhibitor
- use according
- immunomodulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 73
- 239000003112 inhibitor Substances 0.000 claims description 67
- 239000002955 immunomodulating agent Substances 0.000 claims description 55
- 229940121354 immunomodulator Drugs 0.000 claims description 52
- -1 CEACAM Proteins 0.000 claims description 50
- 201000011510 cancer Diseases 0.000 claims description 47
- 230000002584 immunomodulator Effects 0.000 claims description 46
- 229960003301 nivolumab Drugs 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 38
- 229960002621 pembrolizumab Drugs 0.000 claims description 38
- 229940124597 therapeutic agent Drugs 0.000 claims description 34
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 28
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 28
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 28
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 23
- 230000000139 costimulatory effect Effects 0.000 claims description 23
- 102100024263 CD160 antigen Human genes 0.000 claims description 22
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 22
- 239000012190 activator Substances 0.000 claims description 22
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 19
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 19
- 229940043355 kinase inhibitor Drugs 0.000 claims description 19
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 19
- 102000003964 Histone deacetylase Human genes 0.000 claims description 16
- 108090000353 Histone deacetylase Proteins 0.000 claims description 16
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 claims description 14
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 14
- 102000017578 LAG3 Human genes 0.000 claims description 14
- 101150030213 Lag3 gene Proteins 0.000 claims description 14
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 14
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 14
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 14
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 14
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 14
- 239000000556 agonist Substances 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000035475 disorder Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 102100038078 CD276 antigen Human genes 0.000 claims description 12
- 101710185679 CD276 antigen Proteins 0.000 claims description 12
- 101150013553 CD40 gene Proteins 0.000 claims description 12
- 102100035793 CD83 antigen Human genes 0.000 claims description 12
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 12
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 12
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 12
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims description 12
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 12
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 12
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 12
- 101000795169 Homo sapiens Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 12
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 12
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 12
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims description 12
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 12
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 12
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 12
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 12
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 12
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 12
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 12
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 12
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 12
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 12
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- VRQXRVAKPDCRCI-ZNMIVQPWSA-N n-[4-[(1r,3s,5s)-3-amino-5-methylcyclohexyl]pyridin-3-yl]-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide Chemical compound C1[C@H](C)C[C@H](N)C[C@@H]1C1=CC=NC=C1NC(=O)C1=CC=C(F)C(C=2C(=CC=CC=2F)F)=N1 VRQXRVAKPDCRCI-ZNMIVQPWSA-N 0.000 claims description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 12
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 12
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 11
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 102100027207 CD27 antigen Human genes 0.000 claims description 10
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 10
- 102100032257 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 10
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 10
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 10
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 10
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 10
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 10
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 10
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 10
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 10
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 10
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 claims description 10
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 10
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 10
- 229940113306 Ligase inhibitor Drugs 0.000 claims description 10
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 10
- 229940122016 Pim kinase inhibitor Drugs 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 10
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 10
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 10
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 10
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 10
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 10
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 10
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 10
- 201000005787 hematologic cancer Diseases 0.000 claims description 10
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 10
- 230000002519 immonomodulatory effect Effects 0.000 claims description 10
- 239000000436 ligase inhibitor Substances 0.000 claims description 10
- CLRSLRWKONPSRQ-CPOWQTMSSA-N (1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)CC2CCC(CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-CPOWQTMSSA-N 0.000 claims description 9
- 108091008794 FGF receptors Proteins 0.000 claims description 9
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 9
- XIFFUJNWCYQIBQ-UHFFFAOYSA-N 8-(2,6-difluoro-3,5-dimethoxyphenyl)-n-[5-[(dimethylamino)methyl]-1h-imidazol-2-yl]quinoxaline-5-carboxamide Chemical compound COC1=CC(OC)=C(F)C(C=2C3=NC=CN=C3C(C(=O)NC=3NC=C(CN(C)C)N=3)=CC=2)=C1F XIFFUJNWCYQIBQ-UHFFFAOYSA-N 0.000 claims description 8
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 208000032839 leukemia Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 208000025113 myeloid leukemia Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 229950010773 pidilizumab Drugs 0.000 claims description 6
- CLRSLRWKONPSRQ-IIPSPAQQSA-N C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-IIPSPAQQSA-N 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 4
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 229960005184 panobinostat Drugs 0.000 claims description 4
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- 229940125565 BMS-986016 Drugs 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 108010087819 Fc receptors Proteins 0.000 claims description 2
- 102000009109 Fc receptors Human genes 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 102000042838 JAK family Human genes 0.000 claims description 2
- 108091082332 JAK family Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 210000000436 anus Anatomy 0.000 claims description 2
- 210000003443 bladder cell Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000003915 cell function Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000000038 chest Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 210000004392 genitalia Anatomy 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 230000002489 hematologic effect Effects 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 210000004324 lymphatic system Anatomy 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 102200087780 rs77375493 Human genes 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000003741 urothelium Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- UXNYKUAVUQXHDG-UHFFFAOYSA-N 8-(2,6-difluoro-3,5-dimethoxyphenyl)quinoxaline-5-carboxylic acid Chemical compound COC1=CC(OC)=C(F)C(C=2C3=NC=CN=C3C(C(O)=O)=CC=2)=C1F UXNYKUAVUQXHDG-UHFFFAOYSA-N 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 1
- 125000004212 difluorophenyl group Chemical group 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 1
- 108091006082 receptor inhibitors Proteins 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 51
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 45
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 40
- 125000001072 heteroaryl group Chemical group 0.000 description 39
- 125000000753 cycloalkyl group Chemical group 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 33
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 32
- 125000005843 halogen group Chemical group 0.000 description 28
- 125000001424 substituent group Chemical group 0.000 description 27
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 19
- 125000003710 aryl alkyl group Chemical group 0.000 description 16
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 16
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 16
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 16
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 125000004438 haloalkoxy group Chemical group 0.000 description 9
- 125000005311 halosulfanyl group Chemical group 0.000 description 8
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 125000006588 heterocycloalkylene group Chemical group 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004966 cyanoalkyl group Chemical group 0.000 description 3
- 125000004663 dialkyl amino group Chemical group 0.000 description 3
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 description 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 description 2
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 150000005347 biaryls Chemical group 0.000 description 2
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- CAMXNXYVKQNLED-UHFFFAOYSA-N 2-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Chemical compound C1=C(C=2C=3C=CNC=3N=CN=2)C=NN1CC(C#N)C1CCCC1 CAMXNXYVKQNLED-UHFFFAOYSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021191659A JP2022043060A (ja) | 2014-10-03 | 2021-11-26 | 組み合わせ治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059832P | 2014-10-03 | 2014-10-03 | |
| US62/059,832 | 2014-10-03 | ||
| PCT/US2015/053799 WO2016054555A2 (en) | 2014-10-03 | 2015-10-02 | Combination therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021191659A Division JP2022043060A (ja) | 2014-10-03 | 2021-11-26 | 組み合わせ治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535528A JP2017535528A (ja) | 2017-11-30 |
| JP2017535528A5 true JP2017535528A5 (https=) | 2018-11-08 |
Family
ID=54337395
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017517730A Ceased JP2017535528A (ja) | 2014-10-03 | 2015-10-02 | 組み合わせ治療 |
| JP2021191659A Pending JP2022043060A (ja) | 2014-10-03 | 2021-11-26 | 組み合わせ治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021191659A Pending JP2022043060A (ja) | 2014-10-03 | 2021-11-26 | 組み合わせ治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20170209574A1 (https=) |
| EP (2) | EP3662903A3 (https=) |
| JP (2) | JP2017535528A (https=) |
| KR (1) | KR20170066546A (https=) |
| CN (1) | CN107106687A (https=) |
| AU (2) | AU2015327868A1 (https=) |
| BR (1) | BR112017006664A2 (https=) |
| CA (1) | CA2963281A1 (https=) |
| EA (1) | EA201790737A1 (https=) |
| ES (1) | ES2774448T3 (https=) |
| MX (2) | MX378690B (https=) |
| WO (1) | WO2016054555A2 (https=) |
Families Citing this family (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| EP3208612B1 (en) | 2008-04-09 | 2019-09-18 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| CN107898791A (zh) | 2010-06-03 | 2018-04-13 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的应用 |
| TWI674262B (zh) | 2011-01-10 | 2019-10-11 | 美商英菲尼提製藥股份有限公司 | 製備異喹啉酮之方法及異喹啉酮之固體形式 |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| EA201691376A1 (ru) | 2014-02-04 | 2017-01-30 | Пфайзер Инк. | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| RU2016142476A (ru) | 2014-03-31 | 2018-05-07 | Дженентек, Инк. | Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40 |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| TWI716362B (zh) | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| NZ733854A (en) | 2015-02-26 | 2022-07-01 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| TWI715587B (zh) | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| TN2019000101A1 (en) | 2015-05-29 | 2020-07-15 | Bristol Myers Squibb Co | Antibodies against ox40 and uses thereof. |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| PH12017501857B1 (en) | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| WO2017007658A1 (en) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| AU2016297249B2 (en) | 2015-07-23 | 2020-11-12 | Inhibrx Biosciences, Inc. | Multivalent and multispecific GITR-binding fusion proteins |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| EP3370699A1 (en) * | 2015-11-04 | 2018-09-12 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| HK1254635A1 (zh) * | 2015-12-17 | 2019-07-26 | Novartis Ag | C-met抑制剂与pd-1抗体分子的组合及其用途 |
| US20190290759A1 (en) * | 2015-12-28 | 2019-09-26 | Syndax Pharmaceuticals, Inc. | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| WO2017175200A1 (en) * | 2016-04-08 | 2017-10-12 | The Regents Of The University Of California | Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents |
| CA3022267A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| EA201892522A1 (ru) * | 2016-05-05 | 2019-05-31 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Днк-моноклональные антитела, нацеленные на молекулы контрольных точек |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI781934B (zh) | 2016-05-27 | 2022-11-01 | 美商艾吉納斯公司 | 抗-tim-3抗體及其使用方法 |
| US20190183972A1 (en) * | 2016-06-03 | 2019-06-20 | Imclone Llc | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
| RU2754507C2 (ru) * | 2016-06-24 | 2021-09-02 | Инфинити Фармасьютикалз, Инк. | Комбинированная терапия |
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| US20210369746A1 (en) * | 2016-08-01 | 2021-12-02 | Molecular Templates, Inc. | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
| WO2018035395A1 (en) * | 2016-08-19 | 2018-02-22 | Irx Therapeutics, Inc. | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer |
| JP2019524851A (ja) * | 2016-08-24 | 2019-09-05 | イグナイタ インコーポレイテッド | がんを治療するための組み合わせ |
| WO2018049014A1 (en) | 2016-09-07 | 2018-03-15 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
| CN106350488B (zh) * | 2016-09-19 | 2019-09-27 | 大连大学 | 用于治疗肿瘤的pd-1封闭cik的制备方法 |
| KR20190062515A (ko) | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
| TWI764943B (zh) | 2016-10-10 | 2022-05-21 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 |
| SG10201912663YA (en) | 2016-10-11 | 2020-03-30 | Agenus Inc | Anti-lag-3 antibodies and methods of use thereof |
| CA3041684C (en) | 2016-11-01 | 2023-09-26 | Anaptysbio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| WO2018081898A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3042581A1 (en) * | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| CN110662552A (zh) | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
| IL303038B2 (en) | 2016-12-05 | 2024-08-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| UY37594A (es) | 2017-02-07 | 2018-08-31 | Univ Saitama Medical | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer |
| BR112019019597A2 (pt) * | 2017-03-20 | 2020-04-14 | Vaccinex Inc | tratamento de câncer com um anticorpo anti-semaforina- 4d em combinação com um agente de modulação epigenética |
| US20200108066A1 (en) * | 2017-03-30 | 2020-04-09 | Shorn Goel | Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors |
| AU2018241944A1 (en) * | 2017-03-31 | 2019-08-15 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
| EP3606518A4 (en) | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| MX2019012579A (es) * | 2017-04-20 | 2020-07-28 | Univ Chicago | Métodos y composiciones para tratar el cáncer con péptidos de afinidad de mec ligados a anticuerpos inmunoterapéuticos. |
| PE20200859A1 (es) * | 2017-06-02 | 2020-08-25 | Bayer Healthcare Llc | Combinacion farmaceutica que comprende regonafenib y nivolumab como anticancerigeno |
| SG11202000634UA (en) | 2017-07-27 | 2020-02-27 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| WO2019023786A1 (en) * | 2017-08-01 | 2019-02-07 | University Health Network | COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE |
| AU2018328773B2 (en) * | 2017-09-08 | 2023-11-16 | University Health Network | Combination therapies for inhibition of Polo-like Kinase 4 |
| CN111491665B (zh) * | 2017-09-26 | 2024-08-06 | 中外制药株式会社 | 药物组合物 |
| EP3695408B1 (en) * | 2017-10-02 | 2026-01-21 | The Broad Institute, Inc. | Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer |
| KR20200072507A (ko) | 2017-10-19 | 2020-06-22 | 데비오팜 인터네셔날 에스 에이 | 암 치료를 위한 조합 제품 |
| AU2018360386B2 (en) | 2017-11-03 | 2023-11-09 | Aurigene Oncology Limited | Dual inhibitors of TIM-3 and PD-1 pathways |
| CN111386128A (zh) | 2017-11-06 | 2020-07-07 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的联合疗法 |
| CN110248664B (zh) * | 2017-11-28 | 2023-03-03 | 深圳艾欣达伟医药科技有限公司 | 葡磷酰胺的抗癌医药用途 |
| WO2019108589A1 (en) * | 2017-11-30 | 2019-06-06 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating cancer |
| WO2019122941A1 (en) | 2017-12-21 | 2019-06-27 | Debiopharm International Sa | Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule |
| US20200385478A1 (en) * | 2018-01-05 | 2020-12-10 | Biograph 55, Inc. | Compositions and methods for cancer immunotherapy |
| MX2020007312A (es) | 2018-01-08 | 2021-01-08 | G1 Therapeutics Inc | Regimenes de dosificacion superior de g1t38. |
| EP3737373A4 (en) * | 2018-01-10 | 2021-09-08 | Array Biopharma, Inc. | METHODS AND POLYTHERAPY FOR TREATING CANCER |
| CA3091373A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| US20200376035A1 (en) * | 2018-02-26 | 2020-12-03 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising cart and a smac mimetic |
| WO2019172909A1 (en) * | 2018-03-08 | 2019-09-12 | Astrazeneca Pharmaceuticals Lp | Compositions and methods for treating late stage lung cancer |
| WO2019175799A2 (en) | 2018-03-14 | 2019-09-19 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| JP7536295B2 (ja) * | 2018-05-16 | 2024-08-20 | デューク ユニバーシティ | 免疫毒素とチェックポイント阻害剤との組み合わせを用いるネオアジュバントがん処置 |
| CN112566935B (zh) | 2018-05-23 | 2024-12-13 | 百济神州有限公司 | 抗ox40抗体和使用方法 |
| PL3811931T3 (pl) * | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| MX2021000726A (es) * | 2018-07-26 | 2021-03-25 | Bristol Myers Squibb Co | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. |
| TW202012411A (zh) * | 2018-07-31 | 2020-04-01 | 大陸商蘇州亞盛藥業有限公司 | Iap抑制劑與免疫檢查點分子調節劑的組合用於治療癌症的方法 |
| KR102666754B1 (ko) * | 2018-08-21 | 2024-05-17 | 에이비엘바이오 주식회사 | 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도 |
| WO2020071349A1 (ja) * | 2018-10-01 | 2020-04-09 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
| BR112021007448A2 (pt) * | 2018-11-14 | 2021-10-26 | Bayer Aktiengesellschaft | Combinação farmacêutica de anticorpos anti-ceacam6 e anti-pd-1 ou anti-pd-l1 para o tratamento de câncer |
| CN113453678A (zh) * | 2018-11-26 | 2021-09-28 | 德彪药业国际股份公司 | Hiv感染的联合治疗 |
| WO2020132672A1 (en) * | 2018-12-21 | 2020-06-25 | Actinium Pharmaceuticals, Inc. | Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer |
| WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| CA3127776A1 (en) * | 2019-01-30 | 2020-08-06 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
| EP3696191A1 (en) | 2019-02-14 | 2020-08-19 | Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) | Car t-cells for the treatment of cd1a-positive cancer |
| TW202035701A (zh) * | 2019-02-20 | 2020-10-01 | 學校法人埼玉醫科大學 | 用以預測於癌症免疫療法下之長期存活之方法及組合物 |
| EP3928792A4 (en) | 2019-02-20 | 2022-12-14 | Saitama Medical University | BIOMARKERS IN PERIPHERAL BLOOD FOR ASSESSING THE ANTI-TUMORS IMMUNE EFFECT OF RADIATION THERAPY |
| WO2020172233A1 (en) * | 2019-02-22 | 2020-08-27 | The Trustees Of Columbia University In The City Of New York | Treatment of prostate cancer by androgen ablation and il-8 blockade |
| MA55088A (fr) * | 2019-02-28 | 2022-01-05 | Taiho Pharmaceutical Co Ltd | Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| US20200319163A1 (en) * | 2019-03-29 | 2020-10-08 | Georgetown University | Methods and compositions overcoming cancer cell immune resistance |
| CN110179977A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗黑色素瘤、肺癌或结直肠癌的组合药物制剂 |
| KR20220027969A (ko) | 2019-06-28 | 2022-03-08 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 프리리포솜 아나마이신 동결건조물의 제조 |
| ES3049663T3 (en) | 2019-06-28 | 2025-12-17 | Univ Texas | Method of reconstituting liposomal annamycin |
| WO2021011501A1 (en) * | 2019-07-12 | 2021-01-21 | Oregon Health & Science University | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor |
| EP4272837A3 (en) | 2019-08-02 | 2024-02-28 | Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer | Car t-cells against bcma for the treatment of multiple myeloma |
| KR20220061977A (ko) | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Cd39 발현 세포의 adcc 표적화를 통해 t 세포 매개 면역 반응을 촉진 및 강화하기 위한 방법 및 조성물 |
| KR20210028339A (ko) * | 2019-09-04 | 2021-03-12 | 크리스탈지노믹스(주) | Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물 |
| CN120678911A (zh) * | 2019-09-11 | 2025-09-23 | 奥力有限公司 | 用于增强抗体药物的效果的组合物 |
| MX2022003628A (es) | 2019-09-25 | 2022-07-21 | Debiopharm Int Sa | Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente. |
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| KR20220103992A (ko) * | 2019-11-21 | 2022-07-25 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 리포솜 아나마이신에 의한 폐 표적화 항암 요법 |
| US20230002500A1 (en) * | 2019-11-21 | 2023-01-05 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| EP4168451A2 (en) | 2020-06-22 | 2023-04-26 | NGM Biopharmaceuticals, Inc. | Lair-1-binding agents and methods of use thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN112972688A (zh) * | 2021-02-08 | 2021-06-18 | 吉林大学第一医院 | PPARδ抑制剂联合免疫治疗药物在制备抗肿瘤药物中的应用 |
| US20220251218A1 (en) * | 2021-02-10 | 2022-08-11 | Gnt Biotech & Medicals Corporation | Pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer |
| US20240342176A1 (en) * | 2021-07-27 | 2024-10-17 | Guangzhou Joyo Pharmatech Co., Ltd | Pharmaceutical combination and application thereof |
| CN115671289B (zh) * | 2021-07-27 | 2024-04-26 | 广州嘉越医药科技有限公司 | 药物组合及其应用 |
| WO2023043958A1 (en) * | 2021-09-16 | 2023-03-23 | Gt Biopharma, Inc. | Pd-l1 targeting fusion proteins and methods of use thereof |
| EP4234582A1 (en) | 2022-02-28 | 2023-08-30 | Onechain Immunotherapeutics SL | Humanized cd1a targeting moiety for the treatment of cd1a-positive cancer |
| CA3251493A1 (en) | 2022-02-28 | 2023-08-31 | Onechain Immunotherapeutics S.L | Humanized CD1A Targeting Fraction for Treating CD1A-Positive Cancer |
| EP4417623A1 (en) | 2023-02-15 | 2024-08-21 | Fundació Institut de Recerca Contra la Leucèmia Josep Carreras | Ccr9 targeting moiety for the treatment of ccr9-positive cancer |
| JP2026510999A (ja) | 2023-03-21 | 2026-04-10 | バイオグラフ ５５，インク． | Ｃｄ１９／ｃｄ３８多重特異性抗体 |
| US12553903B2 (en) | 2023-06-01 | 2026-02-17 | Cg Pharmaceuticals, Inc | Ivaltinostat combination therapy for treating pancreatic cancer |
| CN117604110B (zh) * | 2024-01-23 | 2024-04-19 | 杭州华得森生物技术有限公司 | 用于乳腺癌诊断和预后判断的生物标志物及其应用 |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
Family Cites Families (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| BR9207175A (pt) | 1992-10-28 | 1995-12-12 | Genentech Inc | Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| ES2308787T3 (es) | 1996-08-16 | 2008-12-01 | Schering Corporation | Antigenos de superficie de celular de mamiferos; reactivos relacionados. |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
| AU2591599A (en) | 1998-02-09 | 1999-08-23 | Genentech Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| ES2246567T3 (es) | 1998-04-15 | 2006-02-16 | Brigham & Womens Hospital | Composiciones para receptores inhibidores de celulas t y usos de las mismas. |
| AU776788C (en) | 1998-12-16 | 2005-10-27 | Warner-Lambert Company | Treatment of arthritis with MEK inhibitors |
| SI2168984T1 (sl) * | 1999-03-25 | 2012-12-31 | Abbott Gmbh & Co. Kg | Človeška protitelesa za vezavo IL-12 in postopki izdelave |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| AU6085700A (en) | 1999-07-12 | 2001-01-30 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| DZ3401A1 (fr) | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7596459B2 (en) | 2001-02-28 | 2009-09-29 | Quadlogic Controls Corporation | Apparatus and methods for multi-channel electric metering |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| AU2003224672B2 (en) | 2002-03-08 | 2010-02-04 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20040047858A1 (en) | 2002-09-11 | 2004-03-11 | Blumberg Richard S. | Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| AU2003300184B8 (en) | 2002-12-30 | 2009-12-03 | 3M Innovative Properties Company | Immunostimulatory combinations |
| JP4638876B2 (ja) | 2003-05-23 | 2011-02-23 | ワイス | Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用 |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| AU2005252110B2 (en) | 2004-06-11 | 2008-09-04 | Shionogi & Co., Ltd. | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| DK1789390T3 (da) | 2004-09-02 | 2012-02-27 | Genentech Inc | Pyridyl-inhibitorer af hedgehog-signalering |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| WO2007004415A1 (ja) | 2005-07-01 | 2007-01-11 | Murata Manufacturing Co., Ltd. | 多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| MX2008002114A (es) | 2005-07-21 | 2008-04-17 | Ardea Biosciences Inc | Inhibidores de n-(arilamino)-sulfonamida de mek. |
| FR2888850B1 (fr) * | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| ES2376771T3 (es) | 2006-08-21 | 2012-03-16 | Genentech, Inc. | Compuestos aza-benzofuranilo y métodos de utilización |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| BRPI0720264B1 (pt) | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| EP2311807B1 (en) | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| AU2008343065B2 (en) | 2007-12-19 | 2012-04-05 | Genentech, Inc. | 5-anilinoimidazopyridines and methods of use |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
| GEP20125502B (en) | 2008-05-23 | 2012-04-25 | Novartis Ag | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
| NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン， エルエルシー | キナーゼインヒビターおよび使用方法 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX2011002365A (es) | 2008-09-02 | 2011-04-04 | Novartis Ag | Derivados de picolinamida como inhibidres de cinasa. |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| JPWO2010030002A1 (ja) | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | 外来性ｇｉｔｒリガンド発現細胞 |
| US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
| AU2009308707A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| DK2424896T3 (en) | 2009-04-30 | 2015-12-14 | Tel Hashomer Medical Res Infrastructure & Services Ltd | The anti-CEACAM1 antibodies and methods of use thereof |
| WO2010136508A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Stem cell targeting |
| SMT201700293T1 (it) * | 2009-07-20 | 2017-07-18 | Bristol Myers Squibb Co | Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative |
| JO3002B1 (ar) | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CN102958942A (zh) | 2009-12-29 | 2013-03-06 | 新兴产品开发西雅图有限公司 | 异二聚体结合蛋白及其应用 |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012177624A2 (en) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
| WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| EP2785743B1 (en) | 2011-12-01 | 2019-08-14 | The Brigham and Women's Hospital, Inc. | Anti-ceacam1 recombinant antibodies for cancer therapy |
| WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
| JO3300B1 (ar) | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| KR101566539B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| BR112015001521A2 (pt) | 2012-07-27 | 2017-11-07 | Novartis Ag | previsão de resposta ao tratamento para inibidor jak/stat |
| CA2916638C (en) | 2012-07-31 | 2021-01-12 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| CN104853776B (zh) | 2012-10-12 | 2021-04-09 | 布里格姆及妇女医院股份有限公司 | 免疫应答的增强 |
| AU2013343425A1 (en) | 2012-11-08 | 2015-06-11 | Novartis Ag | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases |
| AU2013352406A1 (en) | 2012-11-28 | 2015-06-04 | Novartis Ag | Combination therapy |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| EP3082853A2 (en) * | 2013-12-20 | 2016-10-26 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| SG10201900002QA (en) * | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) * | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| US20150259420A1 (en) * | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| JO3663B1 (ar) * | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| ES2771926T3 (es) * | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
-
2015
- 2015-10-02 AU AU2015327868A patent/AU2015327868A1/en not_active Abandoned
- 2015-10-02 EP EP19206634.8A patent/EP3662903A3/en not_active Withdrawn
- 2015-10-02 BR BR112017006664A patent/BR112017006664A2/pt not_active Application Discontinuation
- 2015-10-02 JP JP2017517730A patent/JP2017535528A/ja not_active Ceased
- 2015-10-02 US US15/515,469 patent/US20170209574A1/en not_active Abandoned
- 2015-10-02 CA CA2963281A patent/CA2963281A1/en not_active Abandoned
- 2015-10-02 EP EP15782164.6A patent/EP3200775B1/en active Active
- 2015-10-02 KR KR1020177012013A patent/KR20170066546A/ko not_active Ceased
- 2015-10-02 ES ES15782164T patent/ES2774448T3/es active Active
- 2015-10-02 MX MX2017004360A patent/MX378690B/es unknown
- 2015-10-02 CN CN201580066100.7A patent/CN107106687A/zh active Pending
- 2015-10-02 WO PCT/US2015/053799 patent/WO2016054555A2/en not_active Ceased
- 2015-10-02 EA EA201790737A patent/EA201790737A1/ru unknown
-
2017
- 2017-04-03 MX MX2020005894A patent/MX2020005894A/es unknown
-
2020
- 2020-05-19 US US16/878,155 patent/US20210000951A1/en not_active Abandoned
-
2021
- 2021-07-05 AU AU2021204687A patent/AU2021204687A1/en not_active Abandoned
- 2021-11-26 JP JP2021191659A patent/JP2022043060A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017535528A5 (https=) | ||
| JP7190548B2 (ja) | Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法 | |
| JP7519477B2 (ja) | 非小細胞肺がんを治療するための抗ｂ７－ｈ１および抗ｃｔｌａ－４抗体 | |
| AU2019218125B2 (en) | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| JP2024174916A (ja) | Ｐｄ－１に対する抗体分子およびその使用 | |
| RU2526171C2 (ru) | Комбинация антагониста с-мет и аминогетероарила для лечения рака | |
| JP2017507990A5 (https=) | ||
| RU2745999C1 (ru) | Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии | |
| TW202136274A (zh) | Ｋｒａｓ ｇ１２ｃ抑制劑 | |
| JP2017532372A5 (https=) | ||
| CN120285177A (zh) | Hdac抑制剂和pd-1抑制剂的组合疗法 | |
| AU2018219887A1 (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| BR112016017893B1 (pt) | Conjugado de anticorpo-fármaco, medicamento antitumoral e/ou anticancerígeno, e composição farmacêutica | |
| WO2018152516A1 (en) | Proteins binding cd33, nkg2d and cd16 | |
| JP2021501779A (ja) | 統合的ストレス経路の調節剤 | |
| RU2017112379A (ru) | Сочетанные способы лечения с использованием ингибиторов alk | |
| CA3052767A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2017533266A5 (https=) | ||
| BR112019021880A2 (pt) | Terapia de combinação com conjugado anticorpo anti-axl-droga | |
| WO2023107956A1 (en) | Proteins binding nkg2d, cd16 and 5t4 | |
| JP2018521121A (ja) | （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状 | |
| BR112019021680A2 (pt) | Terapia de combinação com conjugado anticorpo-fármaco anti-cd25?? | |
| CN110898226A (zh) | Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法 | |
| JP2018531278A (ja) | 癌のための併用療法 |